CompBrief BY VELARION

Companies Enliven Therapeutics, Inc.

Enliven Therapeutics CEO salary & total pay, FY2025: $11.9M

Enliven Therapeutics (ELVN) CEO salary, fiscal 2025: Richard Fair was paid a salary of $38,077 and $11,918,926 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Enliven Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Richard Fair's complete compensation dossier

A PDF and a CSV sent to your email: Richard Fair's pay in every fiscal year Enliven Therapeutics, Inc. reported it, line by line, with Richard Fair's equity grants and Enliven Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$11,918,926CEO Richard Fair · source
Say-on-pay support93.89%Latest vote · source

CEO pay, last three years

  • $8,279,751FY2023
  • $5,461,660FY2024
  • $11,918,926FY2025

CEO total pay was $11,918,926 in fiscal 2025 (Richard Fair), up from $5,461,660 in fiscal 2024 (Sam Kintz, the CEO that year).

FY2025: salary $38,077 · bonus $0 · stock awards $0 · option awards $11,880,138

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Enliven Therapeutics, Inc. in fiscal 2025?
As disclosed, Richard Fair (President and Chief Executive Officer) was the highest-paid executive at Enliven Therapeutics, Inc. in fiscal 2025, with total compensation of $11,918,926.
How did shareholders vote on Enliven Therapeutics, Inc.'s executive compensation?
As disclosed, 93.89% of shareholders supported Enliven Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Enliven Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Enliven Therapeutics, Inc. reported total board compensation of $354,000 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Richard Fair$38,077$0$0$11,880,138$0$0$711$11,918,926
President and Chief Executive Officer
Sam Kintz624,154007,952,553316,800015,1408,908,647
Former President and Chief Executive Officer
Helen Collins523,000002,775,279188,280015,1403,501,699
Chief Medical Officer
Ben Hohl480,000002,775,279172,800015,0943,443,173
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Richard Fair$11,918,926———
Sam Kintz8,908,6475,461,6608,279,751↑ +3,446,987
Helen Collins3,501,6992,771,4104,064,839↑ +730,289
Ben Hohl3,443,173———

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The Company provides cash incentive compensation to its named executive officers based on their meeting of one or more corporate performance objectives, with the board selecting challenging goals that are achievable only by strong performance. The compensation committee reviews CEO recommendations and market data to determine total compensation, focusing on company results, individual contribution, and goal achievement.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultant—
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Ben HohlOption145,91660,08422.75—
Ben HohlOption84,791100,20914.85—
Ben HohlOption—171,00022.47—
Ben HohlOption92,056—2.48—
Helen CollinsOption145,91660,08422.75—
Helen CollinsOption84,791100,20914.85—
Helen CollinsOption—171,00022.47—
Helen CollinsOption266,268—2.48—
Richard FairOption—875,00018.77—
Sam KintzOption188,841—1.12—
Sam KintzOption404,363—2.48—
Sam KintzOption320,166—22.75—
Sam KintzOption187,916—14.85—
Sam KintzOption122,500—22.47—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Richard Heyman, Ph.DIndependent · Board Chair · Compensation · Not standing for re-election$46,000—$365,000——$411,000
Jake Bauer, M.B.AIndependent · Audit (Chair) · Compensation61,000—324,985——385,985
Andrew PhillipsIndependent57,500—324,985——382,485
Mika Derynck, M.DIndependent · Audit · Nominating and Corporate Governance52,500—324,985——377,485
Rishi Gupta, J.DIndependent · Audit · Compensation (Chair)52,000—324,985——376,985
Rahul Ballal, Ph.DIndependent40,000—324,985——364,985
Lori Kunkel, M.DIndependent · Nominating and Corporate Governance45,000—243,735——288,735
Richard Fair, M.B.AEmployee director—————0
Scott Garland, M.B.AIndependent · Nominating and Corporate Governance (Chair) · Newly elected——————

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer$325,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 12,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2025
Cash retainers and fees$354,000
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$354,000

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Enliven Therapeutics as a peer

Companies that benchmark against ELVN

1 company names ELVN as a compensation peer

Each company listed discloses ELVN in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ELVN in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Enliven Therapeutics, Inc.2025Richard Fair$38,077$0$11,880,138$0$11,918,926

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-06-0947,572,1533,093,44721,02793.89%Passed
20252025-06-24—————
20242024-06-18—————
20232023-06-23—————
20222022-06-02—————
20212021-06-29—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-06-0993.89%a
20252025-06-24—b
20242024-06-18—c

a. Approved under the standard stated in the filing — “The non-binding, advisory vote to approve the compensation of our named executive officers requires the affirmative vote of the holders of a majority in voting power of the votes cast by the holders of all of the shares of stock present or represented by proxy at the Annual Meeting and voting affirmatively or negatively on such matter (i.e., Proposal No. || Abstentions: Abstentions and broker non-votes, if any, will have no effect on the proposal.”.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Helen CollinsChief Medical Officer2026-05-18D5,000$0$0Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D223419,189Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D1,3024052,402Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D3,47540137,381Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18A5,000212,400CommonForm 4 ↗
Lori Anne KunkelDirector2026-06-05D3543612,680Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-06-05D1,8673566,012Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-06-05D7,77934266,659Common, open-market saleForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-15D272,3224512,259,936Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-15D9,08645409,052Common, indirectForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D1,1334550,694Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D2,59944114,018Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D1,2684354,305Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D6,01800Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D1,2384555,397Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D3,40144149,179Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D1,3794359,001Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17A6,018214,925CommonForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D46,776452,104,920Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D787,0244535,715,149Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D1,4774566,465Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D24,846451,127,511Common, indirectForm 4 ↗
Lori Anne KunkelDirector2026-07-06D5,88951299,421Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-07-06D4,11150205,482Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D63543,397Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2,18453116,669Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2,06352108,085Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D4595223,660Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2315011,563Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17A5,000212,400CommonForm 4 ↗
Dividend-equivalent accruals2026-07-17—1,072——1 insider, 1 accrual row
Ben HohlChief Financial Officer2026-07-17D123546,626Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D2,63853140,823Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D2,56452134,143Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D3695118,997Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D3245016,191Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17A1,07222,659CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D20,49100Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D23,36400Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D27,56700Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D87,37300Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D158,795609,561,587Common, open-market saleForm 4 ↗
Mika K. DerynckDirector2026-08-04A20,49122460,433CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A23,36415346,955CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A27,56725696,894CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A87,3732216,685CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D1,1005965,281Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D3,90058227,650Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-08-17D1,3885982,383Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-08-17D4,63058270,168Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D2405112,356Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D1,8445193,507Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D2,91650145,891Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D3,98200Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D2895114,881Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D2,19451111,270Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D3,53550176,851Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17A3,9821559,133CommonForm 4 ↗
J. Scott GarlandDirector2026-10-01D13,00000Derivative, Class A CommonForm 4 ↗
J. Scott GarlandDirector2026-10-01D13,00047606,719Common, open-market saleForm 4 ↗
J. Scott GarlandDirector2026-10-01A13,00015201,110CommonForm 4 ↗
Kristine M. BallDirector2026-10-14A23,39400Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-10-19D6,01800Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-10-19D6,01838231,546Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-10-19A6,0181589,367CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19D5,00038192,342Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19A5,000212,400CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30D7,30000Derivative, Class A CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30D3,74100Derivative, Class A CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30A7,30018133,590CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30A3,74114,190CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D61482,903Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D4,93947231,300Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17A5,000212,400CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 83 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Helen CollinsChief Medical Officer2026-05-18D5,000$0$0Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D223419,189Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D1,3024052,402Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18D3,47540137,381Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-05-18A5,000212,400CommonForm 4 ↗
Lori Anne KunkelDirector2026-06-05D3543612,680Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-06-05D1,8673566,012Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-06-05D7,77934266,659Common, open-market saleForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-15D272,3224512,259,936Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-15D9,08645409,052Common, indirectForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D1,1334550,694Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D2,59944114,018Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17D1,2684354,305Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-06-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D6,01800Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D1,2384555,397Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D3,40144149,179Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17D1,3794359,001Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-06-17A6,018214,925CommonForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D46,776452,104,920Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D787,0244535,715,149Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D1,4774566,465Common, indirectForm 4 ↗
ORBIMED ADVISORS LLCGreater-than-10% holder2026-06-22D24,846451,127,511Common, indirectForm 4 ↗
Lori Anne KunkelDirector2026-07-06D5,88951299,421Common, open-market saleForm 4 ↗
Lori Anne KunkelDirector2026-07-06D4,11150205,482Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D63543,397Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2,18453116,669Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2,06352108,085Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D4595223,660Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17D2315011,563Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-07-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D1,07200Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D123546,626Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D2,63853140,823Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D2,56452134,143Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D3695118,997Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17D3245016,191Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-07-17A1,07222,659CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D20,49100Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D23,36400Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D27,56700Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D87,37300Derivative, Class A CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04D158,795609,561,587Common, open-market saleForm 4 ↗
Mika K. DerynckDirector2026-08-04A20,49122460,433CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A23,36415346,955CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A27,56725696,894CommonForm 4 ↗
Mika K. DerynckDirector2026-08-04A87,3732216,685CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D1,1005965,281Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17D3,90058227,650Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-08-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-08-17D1,3885982,383Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-08-17D4,63058270,168Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D2405112,356Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D1,8445193,507Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17D2,91650145,891Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-09-17A5,000212,400CommonForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D3,98200Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D2895114,881Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D2,19451111,270Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17D3,53550176,851Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-09-17A3,9821559,133CommonForm 4 ↗
J. Scott GarlandDirector2026-10-01D13,00000Derivative, Class A CommonForm 4 ↗
J. Scott GarlandDirector2026-10-01D13,00047606,719Common, open-market saleForm 4 ↗
J. Scott GarlandDirector2026-10-01A13,00015201,110CommonForm 4 ↗
Kristine M. BallDirector2026-10-14A23,39400Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-10-19D6,01800Derivative, Class A CommonForm 4 ↗
Ben HohlChief Financial Officer2026-10-19D6,01838231,546Common, open-market saleForm 4 ↗
Ben HohlChief Financial Officer2026-10-19A6,0181589,367CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19D5,00038192,342Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-10-19A5,000212,400CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30D7,30000Derivative, Class A CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30D3,74100Derivative, Class A CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30A7,30018133,590CommonForm 4 ↗
Lori Anne KunkelDirector2026-10-30A3,74114,190CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D5,00000Derivative, Class A CommonForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D61482,903Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17D4,93947231,300Common, open-market saleForm 4 ↗
Helen CollinsChief Medical Officer2026-11-17A5,000212,400CommonForm 4 ↗
Sources (102 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Richard Fair. DEF 14A, filed 2026-04-27. Section “Executive Compensation” · page 36. As printed: 11,918,926. View filing ↗
  • Section 01, Sam Kintz. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 8,908,647. View filing ↗
  • Section 01, Helen Collins. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,501,699. View filing ↗
  • Section 01, Ben Hohl. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 3,443,173. View filing ↗
  • Section 08, Richard Heyman, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 411,000. View filing ↗
  • Section 08, Jake Bauer, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 385,985. View filing ↗
  • Section 08, Andrew Phillips. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 382,485. View filing ↗
  • Section 08, Mika Derynck, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 377,485. View filing ↗
  • Section 08, Rishi Gupta, J.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 376,985. View filing ↗
  • Section 08, Rahul Ballal, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 364,985. View filing ↗
  • Section 08, Lori Kunkel, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 288,735. View filing ↗
  • Section 08, Richard Fair, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 08, Scott Garland, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: —. View filing ↗
  • Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-06-05. Form 4, filed 2026-06-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-06-17. Form 4, filed 2026-06-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, ORBIMED ADVISORS LLC 2026-06-22. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-07-06. Form 4, filed 2026-07-08. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-07-17. Form 4, filed 2026-07-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Mika K. Derynck 2026-08-04. Form 4, filed 2026-08-06. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-08-17. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-09-17. Form 4, filed 2026-09-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, J. Scott Garland 2026-10-01. Form 4, filed 2026-10-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kristine M. Ball 2026-10-14. Form 4, filed 2026-10-16. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ben Hohl 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-10-19. Form 4, filed 2026-10-21. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Lori Anne Kunkel 2026-10-30. Form 4, filed 2026-11-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Helen Collins 2026-11-17. Form 4, filed 2026-11-19. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-06-10. Item 5.07 · say-on-pay result. As reported: 93.89% (votes for as printed: 47,572,153). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-18. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 354,000 + equity 0 + all other 0 = 354,000, summed across the director compensation table rows.
  • Enliven Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Enliven Therapeutics, Inc.'s own proxy. As printed: 11,918,926. View filing ↗
Get the full report — $299